Your browser is no longer supported. Please, upgrade your browser.
INCY Incyte Corporation daily Stock Chart
Incyte Corporation
IndexS&P 500 P/E53.99 EPS (ttm)1.41 Insider Own0.40% Shs Outstand214.08M Perf Week1.67%
Market Cap16.30B Forward P/E24.82 EPS next Y3.07 Insider Trans-12.61% Shs Float213.83M Perf Month0.07%
Income305.90M PEG1.21 EPS next Q0.64 Inst Own97.40% Short Float2.33% Perf Quarter-6.47%
Sales2.01B P/S8.12 EPS this Y133.20% Inst Trans0.22% Short Ratio4.36 Perf Half Y-4.13%
Book/sh10.47 P/B7.27 EPS next Y19.38% ROA11.30% Target Price93.65 Perf Year19.22%
Cash/sh7.92 P/C9.61 EPS next 5Y44.67% ROE15.20% 52W Range57.00 - 89.30 Perf YTD19.70%
Dividend- P/FCF34.24 EPS past 5Y23.80% ROI6.30% 52W High-14.76% Beta0.95
Dividend %- Quick Ratio5.60 Sales past 5Y39.60% Gross Margin95.90% 52W Low33.54% ATR2.27
Employees1367 Current Ratio5.60 Sales Q/Q1.60% Oper. Margin14.20% RSI (14)48.98 Volatility2.39% 3.14%
OptionableYes Debt/Eq0.02 EPS Q/Q98.80% Profit Margin15.20% Rel Volume0.66 Prev Close75.77
ShortableYes LT Debt/Eq0.02 EarningsOct 29 BMO Payout0.00% Avg Volume1.15M Price76.12
Recom2.20 SMA200.25% SMA50-3.95% SMA200-5.08% Volume768,395 Change0.46%
Oct-03-19Initiated Mizuho Buy $95
Sep-12-19Initiated BMO Capital Markets Market Perform
Sep-05-19Upgrade Oppenheimer Perform → Outperform $100
Sep-05-19Upgrade JMP Securities Mkt Perform → Mkt Outperform $107
Sep-05-19Resumed Morgan Stanley Equal-Weight $82 → $87
May-21-19Initiated Credit Suisse Neutral $75
May-03-19Downgrade Barclays Overweight → Equal Weight $90 → $82
Apr-11-19Initiated Stifel Hold $82
Apr-03-19Downgrade RBC Capital Mkts Outperform → Sector Perform $89
Jan-24-19Upgrade William Blair Mkt Perform → Outperform
Jan-24-19Upgrade Gabelli & Co Hold → Buy $105
Jan-16-19Downgrade UBS Buy → Neutral
Jan-03-19Upgrade Guggenheim Neutral → Buy
Oct-22-18Upgrade Raymond James Outperform → Strong Buy
Oct-01-18Initiated Cantor Fitzgerald Neutral $73
Sep-25-18Initiated Leerink Partners Mkt Perform
Aug-15-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Aug-01-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jul-13-18Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-26-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Oct-12-19 02:32AM  Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo Business Wire
Oct-11-19 12:40PM  Seattle Genetics Begins Phase III Study on Tucatinib Combo Zacks
Oct-10-19 11:17AM  bluebird Inks Genome Editing Research Deal With Novo Nordisk Zacks
08:00AM  Incyte to Report Third Quarter Financial Results Business Wire
Oct-08-19 06:45AM  Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress PR Newswire
Oct-04-19 11:33AM  Puma Biotech Gets FDA Nod of Labeling Supplement for Nerlynx Zacks
09:30AM  3 Drug Stocks Poised for Gains After Cancer Conference Investopedia
05:28AM  Incyte Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-03-19 04:47PM  Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down Zacks
11:22AM  Merck's Pediatric Filings for Dificid Get FDA's Priority Review Zacks
09:30AM  Is Incyte (INCY) Stock Outpacing Its Medical Peers This Year? Zacks
07:00AM  Amgen, Merck and Others Highlighted Cancer-Drug Developments in Barcelona
Oct-01-19 08:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
Sep-30-19 06:00AM  The 3 Best Health-Care Stocks This Month. And the Worst
Sep-29-19 03:01PM  The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear Benzinga
Sep-27-19 10:47AM  Incyte (INCY) Stock Up 16% YTD on Strong Jakafi Performance Zacks
09:39AM  CORRECTING and REPLACING Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma Business Wire
Sep-26-19 10:46AM  A Big Cancer Conference Starts Tomorrow. Heres What It Means for Merck, Bristol-Myers and Other Drug Stocks.
09:02AM  Incyte Treats First Patient in Phase III Vitiligo Study Zacks
Sep-25-19 07:30AM  Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream in Patients with Vitiligo Business Wire
06:30AM  BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special Targeted Immunotherapy Issue in Prestigious Journals GlobeNewswire
Sep-23-19 07:30AM  Incyte to Host Investor Conference Call from ESMO 2019 Business Wire
Sep-18-19 10:41AM  Merck's Keytruda Combo Gets FDA Nod for Endometrial Carcinoma Zacks
Sep-16-19 06:30AM  BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia GlobeNewswire
Sep-12-19 10:14AM  Is There An Opportunity With Incyte Corporation's (NASDAQ:INCY) 29% Undervaluation? Simply Wall St.
Sep-09-19 05:33PM  BriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49 GlobeNewswire
Sep-06-19 11:48AM  Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA Zacks
10:25AM  Why This Biotech Stock Has 'Limited Downside' After 25% Gain This Year Investor's Business Daily
Sep-05-19 09:36AM  Merck's Keytruda Combination Gets EC Nod for Kidney Cancer Zacks
Sep-04-19 06:57PM  Wall Street Green on Wednesday
Aug-29-19 02:30PM  10 Stocks to Buy for September InvestorPlace
09:31AM  Why Is Incyte (INCY) Down 4.2% Since Last Earnings Report? Zacks
07:39AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Aug-27-19 06:30AM  BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 GlobeNewswire
Aug-26-19 10:30AM  Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study Zacks
Aug-23-19 02:55PM  Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis PR Newswire
Aug-22-19 08:00AM  Incyte to Present at Upcoming Investor Conferences Business Wire
Aug-19-19 10:24AM  Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer Zacks
Aug-14-19 08:53AM  3 Charts That Suggest Now Is the Time to Buy Into Biotech Investopedia
Aug-13-19 12:15PM  Does Incyte (NASDAQ:INCY) Have A Healthy Balance Sheet? Simply Wall St.
Aug-12-19 06:30AM  BriaCell Appoints Richard J. Berman to Board of Directors GlobeNewswire
Aug-03-19 01:15AM  Top Biotech Stocks for February 2019 Investopedia
Jul-30-19 11:03PM  Edited Transcript of INCY earnings conference call or presentation 30-Jul-19 12:00pm GMT Thomson Reuters StreetEvents +6.44%
07:23PM  Incyte Corp (INCY) Q2 2019 Earnings Call Transcript Motley Fool
04:09PM  The No. 1 Biotech Is Flirting With A Buy Point After Its Beat-And-Raise Investor's Business Daily
04:00PM  Here's What You'll Want to Know About Incyte's Impressive Q2 Results Motley Fool
01:06PM  Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y Zacks
08:15AM  Incyte (INCY) Q2 Earnings and Revenues Beat Estimates Zacks
07:00AM  Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs Business Wire
03:10AM  Incyte Earnings, Revenue Beat in Q2
Jul-29-19 04:12PM  Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards? Zacks
Jul-26-19 03:17PM  Exelixis (EXEL) to Report Q2 Earnings: What's in the Cards? Zacks
12:04PM  4 Biotech Stocks Sliding Lower InvestorPlace
11:50AM  Will Strong HIV Sales Drive Gilead's (GILD) Q2 Earnings? Zacks
10:03AM  Will Strong Jakafi Sales Drive Incyte (INCY) Q2 Earnings? Zacks
09:27AM  5 Drug/Biotech Stocks Set to Beat Earnings Estimates in Q2 Zacks
Jul-23-19 10:32AM  Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
06:30AM  BriaCell Announces $350,000 Equity Investment by Board of Directors GlobeNewswire
Jul-16-19 05:24PM  3 stocks that can make you money despite a trade war or recession MarketWatch
07:01AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Jul-11-19 08:00AM  Incyte to Report Second Quarter Financial Results Business Wire
Jul-10-19 10:14AM  Merck's Keytruda sBLAs for 6-Week Dosing to be Reviewed by FDA Zacks
Jul-09-19 01:58PM  5 Immunotherapy Stocks to Keep a Close Eye On
Jul-08-19 10:42AM  Health stocks under pressure in wake of Trump plan to issue executive order on drug pricing MarketWatch
Jul-03-19 02:59PM  With A 12% Return On Equity, Is Incyte Corporation (NASDAQ:INCY) A Quality Stock? Simply Wall St.
10:23AM  Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab Zacks
Jul-02-19 10:56AM  Incyte signs $77.5M collaboration and licensing deal with Chinese biopharmaceutical company American City Business Journals
07:42AM  Incyte enters license pact with Zai Lab to commercialize its cancer treatment in Greater China MarketWatch
07:30AM  Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China Business Wire
Jun-22-19 09:33AM  This would be the worst-case scenario for health stocks, according to UBS MarketWatch
Jun-20-19 09:41AM  The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure Zacks
Jun-19-19 11:20AM  Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal Zacks
10:21AM  Merck's Keytruda Gets 2nd Label Expansion Approval in June Zacks
10:02AM  2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land
Jun-18-19 09:51AM  Cancer Therapy Stocks Soar After Pfizer Deal Investopedia
07:09AM  Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch
Jun-17-19 01:52PM  Nasdaq Outperforms, Helped By Software, Biotech; Bitcoin Trading Heats Up Investor's Business Daily +5.31%
01:10PM  2 Rallying Pharma Stocks Roping In Option Bulls Schaeffer's Investment Research
Jun-15-19 03:25AM  Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo Business Wire
Jun-13-19 09:32PM  Heres What Hedge Funds Think About Incyte Corporation (INCY) Insider Monkey
05:05PM  Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I Zacks
09:31AM  Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock Zacks
08:24AM  Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study Zacks
Jun-12-19 08:33AM  Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer Zacks
Jun-07-19 04:43PM  Getting technical: Stocks love the 'Fed put'; Tesla still in a down trend traders to sell the rally Yahoo Finance Video
05:00AM  9 interesting things heard during BIO 2019 (Photos) American City Business Journals
Jun-06-19 03:26PM  Incyte Begins Phase III Study for Treatment of Duct Cancer Zacks
Jun-05-19 09:00AM  Celgene (CELG) Presents Data on Pipeline Candidates at ASCO Zacks
Jun-04-19 07:30AM  Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Pemigatinib as a First-Line Therapy for Cholangiocarcinoma Business Wire
Jun-03-19 11:52AM  Novartis (NVS) Announces Various Data Presentations at ASCO Zacks
01:45AM  New Data from GEOMETRY mono-1 Study Show Clinically Meaningful Results in Patients with Non-Small Cell Lung Cancer with MET exon-14 Skipping Mutation Treated with Capmatinib Business Wire
Jun-01-19 11:37AM  The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace Benzinga
May-30-19 04:51PM  Mesoblast Starts Rolling BLA Submission for Remestemcel-L Zacks
09:31AM  Why Is Incyte (INCY) Down 1.7% Since Last Earnings Report? Zacks
May-29-19 10:22AM  Biotech Stock Roundup: AMGN's Nuevolution Buyout, CELG, INCY Drugs' Label Expansion Zacks -5.10%
May-28-19 09:06AM  The Zacks Analyst Blog Highlights: Medtronic, TJX, Deere, Incyte and Netapp Zacks
07:45AM  FDA approves Incyte's Jakafi as graft-versus-host disease therapy American City Business Journals
06:30AM  BriaCells Novel Technology and Clinical Data Published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-27-19 09:17AM  Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi Zacks
May-26-19 05:03PM  The Week Ahead In Biotech: ASCO Presentations In The Spotlight Benzinga
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naive acute and chronic GVHD, as well as Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC); and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome, as well as a pivotal program for solid tumors with driver activations of FGF/FGFR. Further, it is involved in developing INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Additionally, the company develops Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Syros Pharmaceuticals, Inc.; and Innovent Biologics, Inc., as well as BriaCell Therapeutics Corp. for treating cancer. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pasquale Maria EEVP & General CounselOct 10Option Exercise65.36775,03318,680Oct 11 04:40 PM
SWAIN PAULA JEVP, Human ResourcesSep 18Option Exercise64.552,500161,37544,112Sep 19 04:34 PM
SWAIN PAULA JEVP, Human ResourcesSep 18Sale80.002,500200,00041,612Sep 19 04:34 PM
Flannelly Barry PEVP & General Manager USSep 17Sale77.712,491193,57616,757Sep 19 04:30 PM
Pasquale Maria EEVP & General CounselSep 09Option Exercise65.36764,96718,603Sep 11 04:29 PM
SWAIN PAULA JEVP, Human ResourcesAug 15Option Exercise64.552,500161,37544,112Aug 19 04:21 PM
SWAIN PAULA JEVP, Human ResourcesAug 15Sale80.962,500202,40041,612Aug 19 04:21 PM
Pasquale Maria EEVP & General CounselAug 09Option Exercise65.361,22379,93518,527Aug 13 04:35 PM
FRIEDMAN PAUL ADirectorAug 06Option Exercise18.3277,9341,427,751333,465Aug 06 06:45 PM
FRIEDMAN PAUL ADirectorAug 06Sale82.2077,9346,406,175255,531Aug 06 06:45 PM
FRIEDMAN PAUL ADirectorAug 02Option Exercise18.3222,066404,249277,597Aug 06 06:45 PM
FRIEDMAN PAUL ADirectorAug 02Sale84.4122,0661,862,591255,531Aug 06 06:45 PM
BIENAIME JEAN JACQUESDirectorAug 02Sale84.7337731,9437,055Aug 05 04:36 PM
BIENAIME JEAN JACQUESDirectorAug 01Sale85.161,347114,7117,432Aug 05 04:36 PM
Flannelly Barry PEVP & General Manager USJul 17Sale79.9195976,63419,248Jul 18 06:13 PM
SWAIN PAULA JEVP, Human ResourcesJul 15Option Exercise64.552,500161,37544,751Jul 16 04:48 PM
SWAIN PAULA JEVP, Human ResourcesJul 15Sale80.002,500200,00042,251Jul 16 04:48 PM
Stein Steven HEVP & Chief Medical OfficerJun 24Sale87.968,357735,08210,805Jun 25 05:46 PM
SWAIN PAULA JEVP, Human ResourcesJun 17Option Exercise64.552,500161,37539,013Jun 18 05:26 PM
SWAIN PAULA JEVP, Human ResourcesJun 17Sale80.002,500200,00036,513Jun 18 05:26 PM
SWAIN PAULA JEVP, Human ResourcesApr 01Option Exercise18.3210,000183,20044,731Apr 02 04:51 PM
SWAIN PAULA JEVP, Human ResourcesApr 01Sale87.0110,000870,10036,513Apr 02 04:51 PM
SWAIN PAULA JEVP, Human ResourcesMar 01Option Exercise18.3210,000183,20046,513Mar 05 04:45 PM
SWAIN PAULA JEVP, Human ResourcesMar 01Sale86.6810,000866,80036,513Mar 05 04:45 PM
BAKER BROS. ADVISORS LPDirectorFeb 26Option Exercise2.8040,000112,00029,288,793Feb 27 05:19 PM
SWAIN PAULA JEVP, Human ResourcesFeb 01Option Exercise18.3210,000183,20041,124Feb 05 04:36 PM
SWAIN PAULA JEVP, Human ResourcesFeb 01Sale81.1910,000811,90031,124Feb 05 04:36 PM
Flannelly Barry PEVP & General Manager USJan 28Sale80.001,00080,0008,944Jan 30 04:22 PM
Wenqing YaoEVP, Head of Discovery ChemJan 17Option Exercise17.7915,354273,14849,763Jan 22 06:04 PM
Wenqing YaoEVP, Head of Discovery ChemJan 17Sale77.6115,3541,191,62434,409Jan 22 06:04 PM
Trower PaulPrincipal Accounting OfficerJan 15Option Exercise17.795,813103,41319,713Jan 17 04:15 PM
Trower PaulPrincipal Accounting OfficerJan 15Sale75.005,813435,97513,900Jan 17 04:15 PM
Flannelly Barry PEVP & General Manager USJan 08Sale75.561,714129,5109,944Jan 10 04:11 PM
Trower PaulPrincipal Accounting OfficerJan 07Option Exercise17.799,187163,43723,359Jan 08 04:42 PM
Wenqing YaoEVP, Head of Discovery ChemJan 07Option Exercise17.7910,000177,90045,217Jan 08 04:46 PM
Trower PaulPrincipal Accounting OfficerJan 07Sale75.009,187689,02514,172Jan 08 04:42 PM
Wenqing YaoEVP, Head of Discovery ChemJan 07Sale75.0010,000750,00035,217Jan 08 04:46 PM
SWAIN PAULA JEVP, Human ResourcesJan 04Option Exercise18.3230,000549,60062,324Jan 08 04:37 PM
SWAIN PAULA JEVP, Human ResourcesJan 04Sale70.0030,0002,100,00032,324Jan 08 04:37 PM
BIENAIME JEAN JACQUESDirectorNov 08Buy68.771,00068,7656,668Nov 09 04:21 PM